TrialJapanese journal of ophthalmology2026

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study.

Hitoshi Ishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.